LegalAug 13, 2026, 09:29 AM
Cytokinetics Sues Bristol-Myers Squibb Over Patent Infringement
AI Summary
Cytokinetics, Incorporated has filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The lawsuit seeks a declaratory judgment that Cytokinetics does not infringe U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The company is also requesting an injunction to prevent the defendants from initiating infringement litigation related to its product MYQORZO®(aficamten) and has demanded a trial by jury.
Key Highlights
- Cytokinetics filed a complaint in the U.S. District Court for the District of Delaware.
- The lawsuit names Bristol-Myers Squibb Company and MyoKardia, Inc. as defendants.
- The complaint seeks a declaratory judgment of non-infringement of U.S. Patent No. 12,616,697.
- Cytokinetics also seeks a judgment declaring the claims of the '697 patent invalid.
- The company requests an injunction against infringement litigation concerning MYQORZO®(aficamten).
- Cytokinetics has demanded a trial by jury on all triable issues.
- The company intends to vigorously assert its legal rights, acknowledging litigation uncertainty.
Price Impact
More from CYTK